GT Medical Technologies, Inc.
- 27/03/2023
- Series C
- $45,000,000
GT Medical Technologies, Inc. (GT), an Arizona-based medical device company, is focused on improving the lives of patients with brain tumors. GT has developed an innovative approach to treatment by combining a conformable collagen matrix with brachytherapy (radiation) seeds. The company's first product, GammaTile™ is protected by 10 US and 2 Canadian issued patents, and 1 EPO patent. The product has the promise to revolutionize treatment for 176,000 patients/year in the US alone. To date, we have treated 120 patients with recurrent brain tumors in a clinical trial at Barrow Neurological Institute (BNI) and observed significant clinical improvement.
- Industry Medical Equipment Manufacturing
- Website https://gtmedtech.com/
- LinkedIn https://www.linkedin.com/company/gt-medical-technologies-inc/
Related People
Matthew LikensFounder
After graduating cum laude from Kent State University with a Bachelors of Business Administration degree and a major in Marketing, Mr. Likens began his professional career with Johnson & Johnson Corporation. He then spent more than twenty years in domestic and international sales, marketing and general management roles at Baxter Healthcare Corporation, culminating in the position of President, Baxter Biotech North America, followed by President of Baxter’s Renal Division in the U.S.
In July of 2006, Mr. Likens became President and CEO and the second employee of Ulthera, Inc., a venture capital-backed start-up company in energy-based aesthetics in Phoenix, AZ. Beginning with European regulatory clearance in late 2008, followed by FDA clearance in September of 2009, Ulthera realized net revenue growth from $0.5M in ’08 to over $117M in 2014 achieving ongoing profitability from 2012. After filing for an IPO in early 2014, Ulthera was acquired by Merz Pharma GmbH for $600M in July of that year. The Arizona Association for Corporate Growth (ACG) recognized this as Transaction of the Year for 2014.
Phoenix Business Journal honored Mr. Likens in 2012, naming him one of Arizona’s Most Admired CEOs.
In June of 2015, Ernst & Young presented Mr. Likens with the Entrepreneur of the Year for the Mountain Desert Region Award, which recognizes outstanding entrepreneurs who demonstrate excellence and extraordinary success in such areas as innovation, financial performance, and personal commitment to their businesses and communities.
He was appointed president and CEO of GT Medical Technologies in October, 2017, a company that developed and markets GammaTile(R) Therapy, seeking to improve the lives of patients with brain tumors. The company is a venture capital-funded start-up and is eight months in to full commercial release in the U.S. with a growing number of adopting medical centers.